Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in <i>EGFR</i>-Mutant Unresectable Stage III NSCLC.

JTO Clin Res Rep · 2026 · PMC12989836 · PMID 41847154

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Last, the HR for EGFR mutation did not reach statistical significance ( Table 3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in &lt;i&gt;EGFR&lt;/i&gt;-Mutant Unresectable Stage III NSCLC.

The sentences

Clinical Outcomes and Safety of Concurrent Chemoradiotherapy in <i>EGFR</i>-Mutant Unresectable Stage III NSCLC.